Doximity: “Doximity is, it’s such a great company, up very big today. Here’s the problem with Doximity, that’s the kind of stock that people have turned on. … I think you hold Doximity for the long run. That’s how you make money.”
Abbott Laboratories: “That’s the reason that individuals have actually been avoiding purchasing the stock, however they sure aren’t avoiding purchasing [rapid Covid test] BinaxNOW. I believe that this thing is going to be with us for a long period of time. Remember, they currently preannounced bad for BinaxNOW. They’re not preannouncing excellent, however Abbott’s got a lot of other things going all out. Let’s not call it a BinaxNOW story. I like Abbott, however I’ve liked it for several years and will continue to do so for the charitable trust and, naturally, the CNBC Investing Club.”
Tilray: “Look, Irwin Simon runs it, used to run Hain. I happen to like him very much. I don’t like the cannabis industry except for the industrial real estate part, which is a REIT. The cannabis industry has just caused a lot of heartache, and between SPACs and cannabis, there are a lot of people who have left our stock market. I don’t want that to happen to you.”
Upwork: “Upwork, I mean, it’s like Indeed. These are like recruitment companies that are very important right now. They do it for high and white-collar people. The stock has had its high, but I think it can go higher. It’s not a bad company.”
Disclosure: Cramer’s charitable trust owns shares of AbbottLabs
Disclaimer
Questions for Cramer?
Call Cramer: 1-800-743- CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, remarks, ideas for the “Mad Money” site? madcap@cnbc.com
